Combination treatment for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two investigational drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer (NSCLC) that has spread or can't be cured with local treatment. The goal is to see if the combination is safe and might help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer (NSCLC) that has spread or can't be removed with surgery.
- You have at least one tumor that can be measured on scans.
- You are able to do your daily activities with little or no help (ECOG performance status 0 or 1).
- Your heart, liver, kidneys, and bone marrow are working well enough.
- You have not had a previous treatment targeting HER3 or a topoisomerase I inhibitor (a type of chemotherapy payload).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.